Product Information: Bromocriptine (Parlodel)
This semi-synthetic derivative of the ergo group is a dopamine receptor agonist and a Prolactin inhibitor.
Its first major anti-aging use is the enhancement of Dopamine, (a key brain neurotransmitter that undergoes an age-related decline). Past the age of 40 it is estimated that “on-average” the healthy person undergoes a Dopamine decline of approximately 13% per decade, (Dean, Fowkes & Morgenthaler). Accordingly, some neurologists have stated that; “if we all live long enough we shall all become senile.” This is due to the fact that abnormally low levels of Dopamine (after 70% to 80% loss) are diagnosed as Parkinson’s disease, hence protection and enhancement of the Dopamine producing neurons is a key strategy for anti-aging medicine. Not surprisingly then, Bromocriptine is sometimes used in conjunction with other drugs, (such as Deprenyl and Sinemet) in the management of Parkinson’s disease, but anti-aging medicine also considers its preventative properties.
Its second major anti-aging use is the inhibition of Prolactin, this hormone is one of the few that actually appears to increase with age. Prolactin is produced by the pituitary gland and its release is inhibited by Bromocriptine.
Prolactin has been described as a “fat synthesis hormone.” This is because one of its primary functions is to trigger lactation, (milk production) and weight gain in pregnancy. In women, Bromocriptine has been used to help restore ovulation, but it also helps to reduce serum Prolactin levels in men, (although the precise role of Prolactin in men is unclear). A further possible need to control age-related Prolactin levels, is offered by some researchers who believe that Prolactin is an immune system suppressant.
Bromocriptine also effects the most famous of all pituitary hormones- Growth Hormone (GH). Bromocriptine increases growth hormone secretion in individuals with normal growth hormone concentrations, but paradoxically suppresses GH secretion in some patients with acromegaly,(a condition of excessive-production of GH). Studies indicate that Bromocriptine does not affect the release of any other anterior pituitary hormones.
An interesting clinical study administered a component of tobacco called DMBA to rats, at a level where it is known to be very effective in producing breast cancer. However, rats that had been pretreated with Bromocriptine completely avoided any cancer development. Bromocriptine therefore appears to also offer itself as a very potent free radical quencher.
One of the most recent studies indicates that Bromocriptine may be a candidate for the treatment of Type-II diabetes. This is because Bromocriptine has been shown to suppress lipogenesis and improve glucose tolerance and insulin resistance.
One animal study suggested that a further action of Bromocriptine is to alter CNS (central nervous system) regulating metabolism, and as such, has another important use in helping to prevent weight gain, (this would be in addition to its improvement of diabetic conditions).
Bromocriptine is a very potent substance and it must not be used by pregnant or lactating women, (unless under the guidance of a physician). Side effects include nausea, dizziness, lowering of blood pressure, hypotension and confusion. The first three are relatively common, especially when undertaking initial use. It is also known to increase fertility, and thus “extra care” and contraception is advised where necessary.
It does contraindicate with psychoactive and hypotensive drugs and other Dopamine enhancing drugs, such as Deprenyl and Sinemet etc. Although often dependant on the dosages used, these should only be administered concurrently under a physician’s guidance. Its effects can also be exaggerated when combined with other ergots, including Hydergine and Nicergoline.
Overall, there is little need to exceed a dosage in excess of 1.25mg or 2.5mg daily for most people, unless treating a serious medical disorder (and therefore only under a physician’s guidance). Bromocriptine has a wide and diverse range of clinically applications, it could be considered to only be an anti-aging medicine for the serious longevist.
Ingredients: Each tablet contains: Bromocriptine mesylate 2.87 mg (equal to 2.5 of base bromocriptine)
Excipients: Colloidal silica, magnesium stearate, polyvinyl pyrrolidine, corn starch, lactose.
Parlodel is available in: Boxes containing 30 2.5-mg tablets, to be taken by mouth.
Pharmaceutical Classification: Prolactin secretion inhibitor with dopaminergic effect.
Parlodel is Recommended for: Galactorrhoea
accompanied or not by amenorrhoea; post-partum effects (Chiari-Frommel);
idiopathy (Aragonz-del Castillo); tumoral effects (Forbes Albright), side
effects from pharmaceutical products (psychotropic and contraceptive drugs).
Prolactin-dependent amenorrhoea without galactorrhoea. Hyperprolactinaemic
infertility. Menstrual disorders (premenstrual syndrome, brief luteinic
phase). Prolactin-dependent male hypogonadism. Acromegaly: The initial
treatment for this problem is surgical or by means of radiotherapy. PARLODEL
is a useful adjuvant in either treatment and may be used without them
in certain cases. Idiopathic and arteriosclerotic Parkinson's disease.
PARLODEL is particularly beneficial to those patients who show a decreasing
response to L-dopa, and in cases where the effects of levodopa therapy
are restricted by the presence of the "on-off" phenomenon. Taking
this product with L-dopa brings about an increased anti-Parkinson effect
which permits a lower dosage of both pharmaceutical products.
Contraindications: If you are expecting a baby or think that you might be, it is unwise to take this product. The safety and effectiveness of PARLODEL (bromocriptine mesylate) has not been confirmed for treatment of adolescents younger than fifteen years of age.
Precautions: In patients with galactorrhoea and prolactin-dependent amenorrhoea, menstrual disorders or acromegaly, PARLODEL may eliminate pre-existing sterility. Women who may become fertile but who do not wish to conceive should therefore adopt a mechanical form of contraception. The exact cause of infertility should be determined before beginning PARLODEL treatment. Pregnancy should be avoided if hypophysial adenoma has been diagnosed. A marked lengthening of the sella turcica or a defect in the field of vision requires, first of all, surgery or radiotherapy. PARLODEL is only recommended should these measures fail. In the absence of hypophysial adenoma and should the patient be anxious to conceive, PARLODEL treatment should be stopped as soon after conception as possible (early pregnancy diagnosis with immunological test) since knowledge of the possible effects of this pharmaceutical product on the development of pregnancy and the foetus is as yet inconclusive. As a precautionary measure in the case of confirmed pregnancy, the possible negative effects of a pathological hypophysial problem associated with the pregnancy should be controlled regularly (for example, checking the field of vision). Sporadic gastrointestinal bleeding has been known to occur in patients with acromegaly, whether they are undergoing PARLODEL treatment, another treatment, or no treatment at all. Until more complete information is available, it is thus preferable for acromegaly patients with case-histories of peptic ulcer to receive some other form of treatment. If it is essential that such patients take PARLODEL, they can soon expect signs of such gastroenteric reactions. Caution is advised when PARLODEL is taken in large doses by patients suffering from Parkinson's disease with case histories of psychotic disorders, serious cardiovascular problems, peptic ulcers or gastroenteric bleeding. Some cases of pleural effusions have been reported in Parkinson patients undergoing long-term high-dosage PARLODEL treatment. Although the causal correlation between PARLODEL and these reports has not been proved, it is still advisable for patients who show inexplicable pleuro-pulmonary signs or symptoms to be examined and the possibility of stopping PARLODEL treatment considered.
Interactions with other medicines: The possibility of interactions between bromocriptine and psychoactive or hypotensive drugs should not be ruled out. Particular caution should be taken with regard to patients undergoing treatment with ergot alkaloids or products which might possibly increase arterial pressure.
Special Warning: For instructions as to the
use of this product during pregnancy or by patients with acromegaly and/or
hypophysial adenoma, see Precautions.
Directions for use:
In Case ov Overdose: Cases of life-threatening overdoses have not been reported. The single maximum dose taken by an adult has been 225 mg. Nausea, vomiting, dizziness, orthostatic hypotension, excessive perspiration and hallucinations have been observed. Treatment of acute intoxication is symptomatic. Metoclopramide may be used for vomiting and hallucinations.
Adverse Effects: During the first days of
treatment, some patients may experience mild nausea and, less frequently,
dizziness, fatigue or vomiting. However these side effects have never
been of such an intensity as to require a suppression of treatment. In
rare cases, PARLODEL may lead to a lowering of blood pressure. For this
reason supervision and evaluations of out-patients are advisable during
the early days of treatment. Should such undesired side effects persist,
the dosage should be reduced. Reversible pallor in fingers and toes caused
by cold should be reported in the case of patients undergoing a prolonged
treatment of 20 mg and more, especially in patients who have previously
suffered from Raynaud's phenomenon. There have also been cases of vasospasm,
hallucinations and confusion, hypotension and diskinesia. Constipation,
drowsiness and, less frequently, psychomotor excitation, leanness of the
jaw and leg cramp have also been reported during treatment of Parkinson's
disease with PARLODEL. At times certain dose-dependent effects may be
controlled by a lowering of the dosage. Postural hypotension may be unpleasant
but can be treated symptomatically.
Special Storage Precautions: Store this product out of the sunlight and at a temperature not exceeding 25ºC.
Attention: Do not use this product following the expiry date
© 2001 - 2008 Biogenesis Laboratories